FREE DAILY STOCK MARKET NEWS

FREE DAILY STOCK MARKET NEWS

COMPANY LOGO

COMPANY OVERVIEW

FivepHusion is a private Australian biotechnology company, founded in 2018 and headquartered in New South Wales. The company is focused on developing Deflexifol™, a novel drug formulation aimed at providing safer and more effective chemotherapy options.

The research and development for Deflexifol™ were originally conducted at the University of Wollongong (UoW), and the intellectual property for this formulation is assigned to FivepHusion. The company maintains an active collaboration with UoW.

FivepHusion's vision is centred on optimising standard cancer care therapies to enhance patient outcomes and quality of life, thereby contributing to a brighter future for patients.

COMPANY INFORMATION

N/A

Website

FivepHusion

2024 – The Year that Biotech Gets its Vibe Back?

2024 – The Year that Biotech Gets its Vibe Back?

2023 was a challenging year for a lot of listed Companies across the globe, as investor sentiment shifted from bad to worse. Companies operating in the pharmaceutical and biotechnology sectors, in particular, appeared to struggle to attract external investment, as the...

FivepHusion’s Strategic Partnerships for Success

FivepHusion’s Strategic Partnerships for Success

FivepHusion recently embarked on a strategic partnership with pharmaceutical powerhouse Pfizer, facilitated through its manufacturing subsidiary Pfizer CentreOne®. This was not the first time the small biotech company used a mutually beneficial collaboration to its...

FivepHusion Reach Milestone in Deflexifol™ Clinical Trial

FivepHusion Reach Milestone in Deflexifol™ Clinical Trial

Treatment has commenced for the initial patient in the Deflexifol™ at Relapse Trial (DART), aimed at investigating paediatric ependymoma and other brain cancers, marking a pivotal moment in FivepHusion's journey towards bringing Deflexifol™ to the market. The...

FivepHusion Trial Deflexifol™ Brain Tumor Treatment

FivepHusion Trial Deflexifol™ Brain Tumor Treatment

FivepHusion maintains its momentum from its recent successful clinical trial results, with the up-and-coming bio-med company announcing the commencement of its next clinical trial to explore the potential of its flagship Deflexifol™ to treat paediatric brain cancer...

FivepHusion Complete Chemotherapy Clinical Trial

FivepHusion Complete Chemotherapy Clinical Trial

FivepHusion has again demonstrated the potential for its flagship Deflexifol™ to revolutionise the standard of care in 5-FU chemotherapy, with a newly completed dose-escalation clinical study highlighting the superior safety and tolerability of Deflexifol™ over...